NCT07323056RecruitingPhase 2
Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
Sacituzumab Tirumotecan and Limertinib for Conversion Therapy in Locally Advanced Potentially Resectable EGFR-mutant Non-small Cell Lung Cancer: A Prospective, Single-arm, Exploratory Clinical Study
Source: ClinicalTrials.gov · Last updated 7 Jan 2026
Brief summary (registry, in English)
This study is a prospective, single-arm, exploratory clinical research aimed at evaluating the efficacy and safety of lucetamab in combination with leucovorin in the conversion therapy of locally advanced potentially resectable EGFR mutation-positive non-small cell lung cancer, providing more robust clinical evidence for the improvement of treatment modalities for EGFR-mutated locally advanced NSCLC. At the same time, it seeks to identify biomarkers that can predict the therapeutic effect of the combination of lucetamab and leucovorin, offering more precise guidance for the selection of clinical treatment plans and enabling patients to receive the optimal treatment regimen.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (estimated)
- First submitted
- 23 Dec 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Jun 2026
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Diseases
- Lung cancer
- NCT number
- NCT07323056
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 36
- From 1 Jan 2026 to the primary completion date, 1 Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Major surgery within 4 weeks before the first dose (excluding diagnostic biopsy)
- Patients with active or previously had and may recur autoimmune diseases
- Currently receiving systemic hormone therapy (such as equivalent to more than 10 mg of prednisone per day or any other form of immunosuppressive therapy within 14 days before the first dose)
Other illness
- Allergy to Sacituzumab Tirumotecan or any of its excipients
- Patients allergic to Limertinib or any of its excipients
- Patients with a history of other primary tumors; patients with a history of allogeneic organ transplantation
- Patients with drug addiction such as drug abuse, long-term alcohol abuse, AIDS or HIV carriers
Lab values
- Patients who have received any EGFR-TKI or TROP2 ADC treatment before
Who the study is looking for
- Sign the informed consent form
- The age of the subjects is over 18 years old
- Patients with non-small cell lung cancer (NSCLC) with EGFR mutation confirmed by pathology
- Confirmed as locally advanced NSCLC (IIIA, IIIB, IIIC) by chest CT, PET-CT or/and EBUS, and MDT discussion concludes that immediate local surgery is not suitable
- Have not received systematic anti-tumor treatment before
- The researcher confirms at least one measurable lesion according to RECIST 1.1 criteria
- Good lung function and able to tolerate surgical treatment
- ECOG score is 0 to 1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Pulmonary Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.